Home / Taiwan Excellence Award / Award Winning Products / Product Details

AmCAD-UT®Detection
Industry type:Health and precision instrument
Product model number:UT-0221 / UT-0222
AmCad BioMed Corporation
award 3

AmCAD-UT is the first thyroid cancer ultrasound CAD system with FDA 510(k) Clearance, CE Mark Certificate and Taiwan Medical Device Marketing Approval.

AmCAD-UT utilizes patented image analysis technology to capture clinical diagnostic features of thyroid neoplasm from 2D ultrasound images. Through quantification and visualization, detailed color images are thereby displayed for substantially improved and more accurate medical ultrasound interpretation. With the increasing global incidence of thyroid cancer, AmCad provides a non-invasive assessment tool for both detection and diagnosis of thyroid cancer, meeting with the trends of future clinical practices.

Currently we are testing features to run AmCAD-UT through web browsers, which enable cloud analysis and online payment service. This will boost efficiency when dealing with customers, and AmCad will be able to provide real-time technical supports to satisfy all AmCAD-UT users.

https://www.amcadbiomed.com/en/product/ut

About AmCad BioMed Corporation

AmCad BioMed Corporation (AmCad) was founded in 2008 and was listed on Taipei Exchange in the March of 2015 (Ticker: 4188). Our breadth of expertise, from R&D to commercialization, have resulted in world’s first FDA cleared ultrasound Computer-Assisted Detection (CAD) devices. AmCad is committed to assisting medical professionals in making efficient and accurate diagnosis through the support of detailed sonographic visualization and quantification. By integrating AI technology with clinicians' expertise, AmCad will continue to pioneer best-in-class imaging solutions that anticipate mainstream medical needs.

https://www.amcadbiomed.com/en

When it comes to ultrasound examination for thyroid, different physicians may arrive at different interpretations over the same image; the inconsistency of the results may reach up to 70%. Even though physicians made a definitive diagnosis and thus performed thyroidectomy, up to 50% of results turned out to be benign. Unfortunately, life-long medication is required for patients who have undergone thyroidectomy.
A reliable approach is needed for the physicians to make faster and more effective interpretations and thus avoid unnecessary thyroidectomy.
AmCAD-UT utilizes patented image analysis technology to capture clinical diagnostic features of thyroid neoplasm from 2D ultrasound images. Through quantification and visualization, detailed color images are thereby displayed for substantially improved and more accurate medical ultrasound interpretation.